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Summary 
 
There has been a dramatic increase in requests for coeliac disease (CD) serological 
screening using IgA tissue transglutaminase antibodies (IgA-tTG). Recently, the UK 
National Institute for Health and Care Excellence has revised its guidance, 
recommending that total IgA should also be measured in all samples. This is justified 
since false negative results may occur with IgA deficiency. However, implementation of 
this guidance will incur considerable expense. Tests that measure IgA-tTG antibodies 
can detect IgA deficiency, indicated by low background signal. This provides an 
opportunity to identify samples containing IgA<0.2g/L, obviating the need for 
unselected IgA measurement. We investigated feasibility of this approach in two centres 
that use the EliA™ Celikey™ assay or QUANTA Lite® ELISA to quantify IgA-tTG 
antibodies. In both cases, total IgA correlated strongly with background IgA-tTG assay 
signal. Using the Celikey™ assay, a threshold of <17.5 response units achieved 100% 
sensitivity (95% confidence intervals 79.4% - 100%) for detection of IgA<0.2g/L, 
circumventing the need for IgA testing in >99% of sera. A similar principle was 
demonstrated for the QUANTA Lite® assay, whereby a threshold optical density of 
<0.0265 also achieved 100% sensitivity (95% confidence intervals 78.2% - 100%) for 
IgA<0.2g/L, avoiding unnecessary IgA testing in 67% of cases. These data suggest that 
CD screening tests can reliably identify samples containing low IgA in a real-life 
setting, obviating the need for blanket testing. However, this approach requires careful 
individualized validation, given the divergent efficiency with which assays identify 
samples containing low IgA.  
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Introduction 
 
It has been hypothesised that fewer than 20% of patients with coeliac disease (CD) have 
been identified worldwide [1, 2]. Increasing awareness of this issue has led to a striking 
increase in IgA tissue transglutaminase (IgA-tTG) antibody test requests [3]. Although 
rates of diagnosis have improved [4, 5], poorly focussed testing is a recognised problem 
[3]. To assist clinicians, NICE issued Clinical Guideline 68 (2009) - Recognition and 
Assessment of Coeliac Disease (https://www.nice.org.uk/guidance; accessed 16-3-
2010). However, rates of test positivity remained unchanged and are little better than 
would be expected from blind screening of the general population [3, 6].  
In 2015, NICE guidance was updated to recommend that IgA should be 
measured in all serum-based CD screening requests [7], aligning with other guidance [5, 
8-10]. This is justified on the basis that false negative results are expected with selective 
IgA deficiency (sIgAD), requiring alternative testing approaches. In sIgAD, IgA is 
undetectable (<0.07g/L) at age 4 years or above, without secondary cause or 
abnormality of other immunoglobulin isotypes [15, 16]. Prevalence of sIgAD is 1 in 600 
[11], although up to 3% of CD patients may be affected [5, 12-14].  
 Partial IgA deficiency (pIgAD) is a much commoner occurrence and is 
characterized by detectable but sub-normal IgA levels [19]. However, pIgAD rarely 
compromises the performance of the IgA tTG test [14, 20, 21]. To mitigate risk further, 
the European Society for Paediatric Gastroenterology Hepatology and Nutrition 
(ESPGHAN) recommends that non-IgA based CD screening tests should be used for 
samples containing IgA<0.2g/L [8]. 
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A requirement for IgA testing of all CD screens would add significant stress to 
overburdened health services. One proposed workaround exploits the known ability of 
IgA-tTG analytical platforms to identify SIgAD [23-29]. Extrapolating from this, we 
hypothesized that algorithms that robustly identify sera containing IgA<0.2g/L would 
obviate the need for blanket IgA measurement. Here, we tested the feasibility of this 
approach in two centres where distinct CD screening tests are performed. 
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Materials and Methods 
 
Detection of IgA tTG antibodies 
Barnet Hospital receives approximately 10,000 requests for CD screening per annum. 
Testing was undertaken using the EliA™ Celikey™ assay (Thermo Fisher Scientific, 
Waltham, MA) run on a Phadia 250 fully automated platform (Thermo Fisher 
Scientific), as recommended by the manufacturers. In brief, wells are pre-coated with 
recombinant human tTG. After addition of serum and washing, bound IgA-tTg antibody 
is detected using beta galactosidase-conjugated anti-IgA secondary antibodies. Next, 4-
methylumbelliferyl-β-D-galactoside substrate is added, which yields a fluorescent 
product. After stopping the reaction with sodium carbonate, fluorescence emission is 
expressed as response units (RU) which are generated automatically by the software 
from a six-point calibration curve.  
 Eastbourne Hospital receives approximately 8,500 requests for CD screening 
annually. Samples were analysed using the QUANTA Lite® R h-tTG IgA ELISA (Inova 
Diagnostics, San Diego CA) on a DS2® automated ELISA platform (Dynex 
Technologies, Worthing, UK) as recommended by the manufacturers. The principle 
underlying assay performance is similar to the Celikey™ assay, except that the 
secondary antibody is peroxidase conjugated. After addition of 3,3’,5,5’ 
tetramethylbenzidine substrate, a blue product is generated. The reaction is stopped 
using sulphuric acid which yields a yellow end-point colour that is read at 450nm. Data 
are expressed as optical density (OD) units which are generated automatically by the 
software from a five-point calibration curve. In both cases, assay readout (RU or OD 
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units respectively) is converted to arbitrary units of IgA-tTG antibodies, given that there 
are no international standards for IgA-tTG antibodies.  
 
Measurement of serum IgA 
Serum IgA at Barnet Hospital was measured using an immunoturbidimetric assay run 
on an Architect ci8200 (Abbott Diagnostics, Lake Forest, IL). At Eastbourne Hospital, 
the Cobas Tina-quant IgA Gen. 2 assay (Roche Diagnostics, Mannheim, Germany) was 
used.  
 
Quality assurance and quality control  
Both laboratories participate in United Kingdom National External Quality Assessment 
Service (UK NEQAS) schemes for all assays performed. For each assay, internal 
quality control was performed throughout using independently sourced third party 
quality control material. 
 
Statistical analysis 
The Shapiro-Wilk normality test was performed using SPSS (version 24) and 
demonstrated that data were not normally distributed. Consequently, non-parametric 
statistical testing was used throughout. Kendall’s tau b rank correlation was calculated 
using Wessa, P. (2017), Free Statistics Software, Office for Research Development and 
Education version 1.1.23-r7, URL http://www.wessa.net/ ; accessed June 25th, 2016 to 
April 14th, 2017). Median age of patients tested at both sites was compared using the 
Mann Whitney U test, which was performed using SPSS. Receiver operating 
characteristic (ROC) analysis was performed using Graphpad Prism 6.0g. In all cases, 
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two-sided p values are shown. Ethical approval was not required for this analysis and all 
data were fully anonymized throughout the analysis. Age related reference ranges for 
serum IgA were taken from [22]. 
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Results 
 
Detection of low IgA containing samples using the EliA™ Celikey™ assay 
The relationship between serum IgA and RU generated using the EliA™ Celikey™ 
assay was investigated in a data set comprising 367 consecutive and age unselected tests 
in which RU was below 100 (median age 22 years; Fig. 1a). Strong correlation between 
these two parameters was observed (Kendall tau b 0.496, p=0). There was also a 
significant, albeit weak, correlation between RU and age (Kendall tau b 0.19, p=1.2 
x10-7), in keeping with the age-dependent nature of the normal range for IgA [22].   
Next, we explored whether background signal reported by these assays could be 
used to identify all samples containing IgA<0.2g/L, a level below which IgA-tTG 
testing becomes less robust [8]. A receiver operating characteristic (ROC) curve was 
plotted that employs RU as determined in the EliA™ Celikey™ assay to discriminate 
between samples containing IgA<0.2g/L or >0.2g/L (Fig. 1b). Close to perfect test 
performance is indicated by the area under the curve of 0.99. Using an RU threshold of 
17.5, 100% sensitivity (95% confidence intervals 79.4% - 100%) was achieved for all 
samples containing IgA<0.2g/L. At these low RU levels, a strong correlation between 
RU and serum IgA was noted (Kendall tau b 0.95, p=0; Fig. S1). Samples with an 
RU<17.5 contained IgA<0.2g/L in 57% of cases (Fig. S1). 
 
Validation of the threshold to detect low IgA using the EliA™ Celikey™ assay 
Next, we tested this algorithm using a prospectively collected validation data set 
comprising 100 consecutive tests in which RU was <50 (Fig. 1c). In this unselected 
sample (median age 11.5 years; Fig. 1c), a strong correlation was observed once again 
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between serum IgA and RU (Kendall tau b 0.504; p=0; Fig. 1c). All samples containing 
IgA<0.2g/L fell below the threshold RU of 17.5. 
 
Detection of samples containing low IgA using QUANTA Lite® IgA-tTG ELISA 
To test applicability of this strategy to an alternative IgA-tTG assay, we undertook a 
similar analysis using the QUANTA Lite® IgA-tTG ELISA. All sera submitted for 4 
randomly selected and sequential CD testing runs (n=264; median age 33 years) were 
analysed. Correlation between IgA and optical density units was strong (Kendall tau b 
0.653 (p=0); Fig. 2a).  
ROC curve analysis indicated that a threshold OD of 0.0265 or below allowed 
the detection of all samples containing IgA<0.2g/L (95% confidence intervals 78.2% - 
100%; Fig. 2b). However, only 15/87 (17.2%) samples with an OD below the threshold 
contained IgA<0.2g/L (Fig. S2). Correlation between serum IgA and OD levels below 
this threshold was also significant (Kendall tau b 0.346; p = 4.6 x 10-6).  
 
Validation of the threshold to detect low IgA using QUANTA Lite® IgA-tTG 
ELISA 
To validate the ability of the QUANTA Lite® ELISA to discriminate IgA<0.2g/L and 
>0.2g/L, a consecutive age unselected series of 103 sera in which OD was at or above 
the threshold (0.0265 – 0.04 OD units), were analysed for IgA. Although correlation 
between OD units and IgA was weaker (Kendall tau b 0.169; p = 0.014; Fig. 2c), no 
sample contained IgA <0.2g/L (range 0.54g/L – 2.86g/L).  
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Discussion 
 
This study presents independent audits that investigated whether two IgA-tTG antibody 
assays could robustly identify sera containing IgA<0.2g/L. This threshold was selected 
since ESPGHAN recommends that non-IgA based tests should be used in this setting 
[8]. Although low levels of IgA may influence RU or OD units in an unpredictable 
manner (particularly given that it is a rare event), the approach proposed here could 
eliminate the need for total IgA testing in the majority of cases. Using the Celikey™ 
assay, most samples with RU<17.5 contained low IgA. Given that <1% of samples 
tested yield an RU below this threshold, IgA testing could be avoided in over 99% of 
cases. Similarly, identification of a safe threshold for identifying low IgA levels using 
the QUANTA Lite® ELISA could obviate the need for measurement of total IgA in 
67% of cases.  
If test requesting patterns seen at these district general hospitals are extrapolated  
nationally, it is estimated that 1–1.2 million requests for CD screening are made 
annually. A serum IgA test has been fully costed at £30 (http://www.thepathlab.co.uk/; 
accessed 22-2-2017) meaning that implementation of updated NICE guidance would 
cost £30 million per annum. If our findings are confirmed, virtually all of these funds 
could be recouped by implementation of a threshold RU on the Celikey™ assay. 
However, laboratories need to carefully validate and verify such algorithms locally. 
Alternatively, laboratories may offer combined IgG based testing (eg IgG deamidated 
gliadin peptide antibodies). These also perform well as CD screening tests when IgA is 
deficient although this would represent a more costly approach. 
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Our study has a number of limitations. First, we have demonstrated applicability 
of this method to two of more than 25 assays available to measure IgA-tTG antibodies. 
Second, comparison between the performance of these assays is not possible given the 
different numbers of samples tested, with different age distribution of patients. Third, 
the possibility of inadvertent ascertainment bias should be considered. Although our 
analysis was undertaken with unselected serum samples, it is noteworthy that an outlier 
population in which low RU accompanied higher IgA levels (Celikey™ assay) was 
more apparent in the training data set compared to the validation set. Ascertainment bias 
is a well-recognised issue in many studies of CD screening serology [30]. 
The need for blanket IgA testing of coeliac screens has been questioned since it 
rarely unmasks a diagnosis of CD and may lead to unnecessary biopsy [31, 32]. It also 
increases workload and test turnaround time and marginally increases the negative 
predictive value of the IgA-tTG test (from 99.8% to 99.9%), but at a cost of over 
$32,605 per false negative test missed [33]. We also encountered issues with confused 
users seeking advice on how to investigate borderline high or low IgA results that had 
not been requested in the first instance and which were of dubious clinical significance. 
NICE responded to these points, arguing that application of IgA-tTG tests to 
identify sIgAD represents the incorrect use of these assays [34]. NICE speculated that 
false positive results might arise due to rheumatoid factor or haemolysis. No evidence 
was presented in support of these concerns and we did not identify any such issues in 
these audits. NICE highlighted the potential benefit of detecting immunodeficiency 
using blanket IgA testing, an incident so rare to warrant reporting [35]. We view this as 
an inappropriate use of CD screening testing. Blind screening is rarely cost effective and 
the commonest immunodeficiency that would be detected is sIgAD, for which screening 
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cannot be justified on the basis of cost-benefit analysis. The updated NICE guideline 
reverses their previous recommendation to check for IgA deficiency “if the laboratory 
detects a low or very low optical density on IgA-tTG test”. Consideration should be 
given to reinstatement of this earlier recommendation. Such an approach can be adapted 
to maintain consistency with ESPGHAN guidance [8] but must be dependent upon the 
ability of the laboratory to set a robust threshold that identifies all low IgA samples.  
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Figure Legends 
 
Fig 1. Use of the EliA™ Celikey™ assay to detect sera containing low levels of IgA. 
(a) A training data set was generated using 367 consecutive CD screening samples with 
RU<100. Correlation between IgA and RU is shown together with age distribution of 
patients. The lower end of the IgA reference range for each age cohort is shown in 
brackets. (b) Receiver operating characteristic curve indicating the selection of the RU 
threshold for optimum assay performance. (c) To validate this threshold, a data set was 
generated using a consecutively analysed set of 100 sera in which RU was <50. 
Correlation between IgA and RU is shown together with age distribution of patients. 
Mo – months; yr – years. 
 
Fig 2. Use of the QUANTA Lite® ELISA assay to detect sera containing low levels of 
IgA. (a) Two hundred and sixty four consecutively submitted CD screening samples 
were analysed for IgA content. Correlation with OD units is shown together with age 
distribution of patients. The lower end of the IgA reference range for each age cohort is 
shown in brackets. (b) Receiver operating characteristic curve indicating the selection of 
the RU threshold for optimum assay performance. (c) To validate this threshold, a data 
set was generated using a consecutively analysed set of 103 sera in which OD was at or 
above the optimised threshold (range 0.0265 – 0.04 OD units). Correlation between IgA 
and RU is shown together with age distribution of patients. Mo – months; yr – years. 
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